---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-24-000108"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:57:17.792923+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M

## Summary
- Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.
- Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.
- 2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.
- Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).
- ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval.

## SEC filing metadata
- accession: 0001576280-24-000108
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/gh-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-24-000108
- JSON: https://secwatch.observer/filing/0001576280-24-000108.json
- Plain text: https://secwatch.observer/filing/0001576280-24-000108.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.
  - Period: full year 2024
  - Revenue: $675 to $685 million
  - Guidance: raised
  - Result: guidance update
  source text: Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.
  - Period: the quarter ended March 31, 2024
  - Revenue: $168.5 million
  - Net income: $115.0 million
  - EPS: $0.94
  - Result: reported results
  source text: Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.